Gilead Sciences Inc. (NASDAQ:GILD) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on Gilead to $151 from $147 with an Overweight rating on the shares. The firm informed investors that the regulatory and political uncertainties currently weighing on biopharma are expected to subside. As these policy overhangs fade, Morgan Stanley anticipates a shift in market attention back to the industry’s core financial and operational performance. Later, on ...

Group 1 - Gilead Sciences, Inc. is experiencing strong performance in a challenging biotech market, with its stock significantly outperforming peers [1] - The company reported an 8% year-on-year growth in 2024, driven by demand-led volume growth in key products such as BIKTARVY, DESCOVY, and its oncology and liver portfolios [4] - For 2025, Gilead's guidance indicates a flat year-over-year product sales growth of approximately -0.5%, excluding BIKTARVY, with expectations for continued growth in the coming years [4]